Erasca, Inc. (NASDAQ: ERAS) is a Healthcare company (Biotechnology) with a market capitalization of $5.3B. The Maz Rating grades it against the other companies in its sector.
Erasca, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $15.11, Erasca, Inc. trades at 5.7x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -61.7%, return on invested capital of -18.5% and a free cash flow yield of -2.1%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 14.89. Over the past 52 weeks the share price ranged from $2.52 to $24.28, with a beta of 0.65.
Erasca, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 9 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.